ClinicalTrials.gg
Status unknownNCT03249480Updated Aug 15, 2017

Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency

A Phase 4 interventional study of PEG-somatropin in Growth Hormone Deficiency, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Status unknown at 28 sites in China. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Jan 2015, registered Jul 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
900
Allocation
Not applicable
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Planned enrollment
Largest of 60
900 · median 66
Started
2015
with 2 others
Phase 4
19 of 60
none open now
Registered
54th of 60
by date
Lead sponsor
10 of 60
Changchun GeneScience Pharmaceutical Co., Ltd.

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one has the largest planned enrollment, is one of 3 that started in 2015, is one of 19 in phase 4, and was the 54th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

To Evaluate the safety and efficacy of PEG Somatropin in the treatment of children with growth hormone deficiency, as well as to study the dosage of PEG Somatropin.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed as GHD before starting treatment, according to medical history, clinical symptoms and signs, GH provocation tests and imaging and other examinations:

    1. According to statistical height data of physical development of Chinese children in nine cities in 2005, the height is lower than 3rd percentile growth curve of the same age, same sex normal children;
    2. Height velocity (HV) ≤5.0 cm / yr;
    3. GH provocative tests (with two drugs of different mechanism of action) confirmed plasma GH peak \<10.0 ng / ml;
    4. bone age for girl≤9 years old, for Boy≤10 years old, bone age is one year or more later than the actual age, that is the actual age - bone age ≥ 1 year;
  • Before puberty (Tanner I stage), age≥3 years old, male or female;
  • Have not received hormone therapy within 6 months;
  • Subjects is willing and able to cooperate to complete scheduled visits, treatment plans and laboratory tests and other procedures, to sign .

Exclusion criteria

Exclusion Criteria:

  • Dysfunction of liver and kidney (> 2 times the , Cr> upper limit of normal);
  • Patients positive for c-antibody (HBcAb), hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg);
  • Patients with known to PEG Somatropin or Somatropin or any other components of the study product;
  • Patients with severe cardiopulmonary or hematological diseases, a current or past history of malignant tumors, immunodeficiency diseases, or mental diseases;
  • Potential cancer patients (family history);
  • Patients with diabetics;
  • Patients with other growth disorders, such as Turner's syndrome, sexual physical delayed puberty, Laron syndrome, growth hormone receptor deficiency, girls with slowly growing who did not rule out chromosomal abnormalities;
  • Patients with congenital bone dysplasia or scoliosis;
  • Subjects took part in other clinical trial study during 3 months;
  • Other conditions in which the investigator preclude enrollment into the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    PEG-somatropin

    30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.

    Biological: PEG-somatropin

Interventions

  • BiologicalPEG-somatropin

    30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.

06

What researchers measure

Primary outcomes

  1. Ht SDSca (Height Standard Deviation Score for Chronological Age)

    Ht SDSca was calculated by dividing the difference between the actual height of a patient and the mean height of the population for that chronological age by the standard deviation (SD) of the height of the population for that chronological age

    Time frame: Baseline

  2. Change of yearly growth velocity from baseline to 26 weeks

    Height velocity calculate by formula

    Time frame: Baseline, 26 weeks after initiating treatment

  3. Ht SDSca

    Ht SDSca was calculated by dividing the difference between the actual height of a patient and the mean height of the population for that chronological age by the standard deviation (SD) of the height of the population for that chronological age

    Time frame: 26 weeks after initiating treatment

Secondary outcomes

  1. Ht SDSBA (Height Standard Deviation Score for Bone Age)

    Time frame: Baseline,26 weeks after initiating treatment

  2. IGF-1 SDS (IGF-1 Standard Deviation Score)

    Time frame: Baseline,26 weeks after initiating treatment

  3. IGFBP-3 SDS (IGFBP-3 Standard Deviation Score)

    Time frame: Baseline,26 weeks after initiating treatment

  4. Skeletal maturity

    Skeletal maturity=(Bone Age at 26 weeks-Bone Age at baseline)/treatment duration

    Time frame: Baseline,26 weeks after initiating treatment

07

Study locations

28 of 28 sites recruiting
  • Anhui Provincial Children's Hospital
    Hefei, Anhui, China
    Recruiting
  • Fuzhou Children s Hospital
    Fuzhou, Fujian, China
    Recruiting
  • Sun Yat-Sen Memorial Hospital
    Guangzhou, Guangdong, China
    Recruiting
  • The Second Hospital of Hebei Medical University
    Shijiangzhuang, Hebei, China
    Recruiting
  • Children's Hospital of Hebei Province
    Shijiazhuang, Hebei, China
    Recruiting
  • The First Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang, China
    Recruiting
  • Children's Hospital of Zhengzhou
    Zhengzhou, Henan, China
    Recruiting
  • Henan Provincal People's Hospital
    Zhengzhou, Henan, China
    Recruiting
  • The First Affiliated Hospital of Henan University of TCM
    Zhengzhou, Henan, China
    Recruiting
  • Union Hospital, Tongji Medical College, HUST
    Wuhan, Hubei, China
    Recruiting
  • Wuhan Children's Hospital
    Wuhan, Hubei, China
    Recruiting
  • Hunan Children's Hospital
    Changsha, Hunan, China
    Recruiting
  • Maternal & Child Health Hospital of Guangxi Zhuang Autonomous Region
    Nanjing, Jiangsu, China
    Recruiting
  • Nanjing Children's Hospital
    Nanjing, Jiangsu, China
    Recruiting
  • Children's Hospital of Soochow University
    Suzhou, Jiangsu, China
    Recruiting
  • Wuxi Children's Hospital
    Wuxi, Jiangsu, China
    Recruiting
  • Xuzhou Children's Hpspital
    Xuzhou, Jiangsu, China
    Recruiting
  • Dalian Children's Hospital
    Dalian, Liaoning, China
    Recruiting
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi, China
    Recruiting
  • Xi'an Children's Hospital
    Xi'an, Shanxi, China
    Recruiting
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
    Recruiting
  • Kunming Children's Hospital
    Kunming, Yunnan, China
    Recruiting
  • Second Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
    Recruiting
  • The First People's Hospital of Yunnan Province
    Kunming, Yunnan, China
    Recruiting
  • China-Japan Friendship Hospital
    Beijing, China
    Recruiting
  • Peking University Third Hospital
    Beijing, China
    Recruiting
  • Shenzhen Children's Hospital
    Shenzhen, China
    Recruiting
  • Tianjin Medical University General Hospital
    Tianjin, China
    Recruiting
08

References and documents

Publications

  • Chen J, Zhong Y, Wei H, Chen S, Su Z, Liu L, Liang L, Lu P, Chen L, Chen R, Ni S, Wang X, Li L, Wang Y, Xu X, Xiao Y, Yao H, Liu G, Jin R, Cao B, Wu D, Su C, Li W, Qin M, Li X, Luo X, Gong C. Polyethylene glycol recombinant human growth hormone in Chinese prepubertal slow-growing short children: doses reported in a multicenter real-world study. BMC Endocr Disord. 2022 Aug 9;22(1):201. doi: 10.1186/s12902-022-01101-8. PubMed 35945517 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2015 (actual). Primary completion is estimated for Aug 2017, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2017
First posted
Aug 15, 2017
StartActual
Jan 2015
Primary completionEst.
Aug 2017
Last update
Aug 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03249480
Collaborators
Beijing Children's Hospital, Tianjin Medical University General Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Dalian Children's Hospital, Xian Children's Hospital, Wuhan Children's Hospital, Fuzhou Children s Hospital, Anhui Provincial Children's Hospital, Hunan Children's Hospital, Shenzhen Children's Hospital, Children's Hospital of Hebei Province, Second Affiliated Hospital of Xi'an Jiaotong University, Zhengzhou Children's Hospital, China, Children's Hospital of Soochow University, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, First Affiliated Hospital of Kunming Medical University, Kunming Children's Hospital, The First People's Hospital of Yunnan, Xuzhou Children's Hopspital, Henan Provincial People's Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, First Affiliated Hospital of Harbin Medical University, The Second Hospital of Hebei Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Union Hospital of Tongji Medical College of HUST, Wuxi Women's & Children's Hospital, The Second Affiliated Hospital of Kunming Medical University, Nanjing Children's Hospital
Responsible party
Sponsor
First posted
Aug 15, 2017
Start date
Jan 2015
Primary completion
Aug 2017 (estimated)
Last update
Aug 15, 2017

Study contacts

Xiaohua Feng
Contact
fengxiaohua@gensci-china.com
13610794989
Chunxiu Gong
principal investigator · Beijing Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion